Результаты поиска

Изучение роли EBV в многочисленных склерозных патогенезах с помощью взаимодействия EBV.

Вирус Эпштейн-Барр (ЭБВ) является известным фактором риска в связи с множественным склерозом (МС), несмотря на то, что основополагающие молекулярные механизмы неясны и включают в себя многочисленные иммунные пути. Кроме того, до сих пор не реализована конечная роль EBV в патогенезе MS. С другой стороны, Cytomegalovirus (CMV) был определен в качестве защитного фактора для MS. ЦЕЛИ: Данное исследование направлено на выявление связанных с MS генов, которые пересекаются с EBV, и изучение их выражения в иммунных и глиальных подтипах клеток. Мы использовали P-HripSTer, GWAS и Human Protein Atlas (HP

Совпадение в полном тексте источника
… The same analysis was performed for CMV, identifying a gene pool for all different cell subtypes. The comparison between the two viruses was depicted by Venn diagrams by the ggvenn R package (n 0.1.10). …

Abstracts from the 6th Annual Conference of Emirates Society of Internal Medicine (ESIM) 2025.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Keyword Index for Volume 100

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy.

Plasmacytoid dendritic cells (pDCs) are multifaceted immune cells with a wide range of innate and adaptive immunological functions. They constitute the first line of defence against multiple viral infections and have also been reported to actively participate in antitumor immune responses. The clinical implication of the presence of pDCs in the tumor microenvironment (TME) is still ambiguous, but it is clear that pDCs possess the ability to modulate tumor-specific T cell responses and direct cytotoxic functions. Therapeutic strategies designed to exploit these qualities of pDCs to boost tumor-

Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview.

Over the past years, the identification of genetic alterations in oncogenic drivers in non-small cell lung cancer (NSCLC) has significantly and favorably transformed the outcome of patients who can benefit from targeted therapies such as tyrosine kinase inhibitors. Among these genetic alterations, anaplastic lymphoma kinase (ALK) rearrangements were discovered in 2007 and are present in 3-5% of patients with NSCLC. In addition, radiotherapy remains one of the cornerstones of NSCLC treatment. Moreover, improvements in the field of radiotherapy with the use of hypofractionated or ablative stereo

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.

BACKGROUND: Tumour agnostic therapies represent a paradigm shift in oncology. BRAF inhibitors have demonstrated efficacy in melanoma. However, their role in non-melanomatous cancers was originally contentious. This systematic review aims to evaluate the safety and efficacy of BRAF-targeted therapies, both as monotherapy and in combination with other targeted therapies, in BRAF-mutated, non-melanomatous tumours. METHODS: A systematic search of MEDLINE, PubMed, EMBASE and Cochrane CENTRAL was conducted from January 2010 to January 2025. Eligible studies included prospective and retrospective tr

Fingolimod и риск заболевания раком кожи у лиц с множественным склерозом: протокол когортного исследования на основе популяции.

ВВЕДЕНИЕ: Для изучения последствий рака кожи у лиц с множественным склерозом (MS), обработанных финголимодом, необходимы долгосрочные исследования по вопросам безопасности населения с применением передовых методов установления причинно-следственных связей, в том числе с активным компаратором с дизайном новых пользователей. Цель этого исследования состоит в том, чтобы охарактеризовать протокол изучения взаимосвязи между использованием финголимодов и заболеваемостью раком кожи у лиц с НР. МЕТОДЫ И АНАЛИЗ: Мы будем использовать данные об административном здоровье населения из двух канадских прови

Talquetamab in multiple myeloma.

Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting. It demonstrated a similar efficacy profile and durability of response to teclistamab, the first bispecific antibody therapy to be approved in multiple myeloma. Additionally, it has less infections than teclistamab but demonstrates unique class-specific side effects including skin, oral, and nail-related adverse events. Despite this, it is still a highly efficacious

Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights.

Brexit was presented as an opportunity to promote innovation by breaking free from the European Union regulatory framework. Since the beginning of 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) has operated as the independent regulatory agency for the United Kingdom. The MHRA's regulatory activity in 2021 was analyzed and compared to that of other international regulatory bodies. The MHRA remained reliant on EU regulatory decision-making for novel medicines and there were significant regulatory delays for a small number of novel medicines in the UK, the reasons being so fa

Keyword Index for Volume 103

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.

This meta-analysis assessed oncolytic virus therapy's efficacy for intermediate-to-advanced solid tumors. We systematically searched PubMed, Cochrane Library, and Embase databases until March 6, 2025. Our review included 87 studies, involving 5,385 individuals, encompassing 75 clinical trials and 12 retrospective studies. Patient response rates were as follows: complete response (CR) 11%, partial response (PR) 18%, stable disease (SD) 32%, and progressive disease (PD) 32%. The overall response rate (ORR) was 29%, and the durable response rate (DRR) was 39%. Comparing oncolytic virus therapy to

Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting both upper and lower motor neurons. ALS is classically characterized by painless progressive weakness, causing impaired function of limbs, speech, swallowing, and respiratory function. The disease is fatal within 2-4 years, often the result of respiratory failure. The pathologic hallmark for a majority of ALS cases is aberrant cytoplasmic accumulations of the nuclear protein TAR-DNA binding protein (TDP-43). A total of 10-15% of ALS can be attributed to a single gene mutation, known as genetic or "familia

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Correlation between Polymorphisms of Vitamin D Metabolism Genes and Perianal Disease in Crohn's Disease.

Although the role of vitamin D (VD) in the pathogenesis and progression of Crohn's disease (CD) is known, the association between single-nucleotide polymorphisms (SNPs) of genes linked to vitamin D pathway and CD risk is still under study. Furthermore, no significant association has been previously found between these SNPs and perianal CD (pCD), a severe phenotypic manifestation of CD that may present as perianal fistula, abscess, and recto-vaginal fistula. Among the mechanisms involved in its pathogenesis, local inflammation and intestinal microbiota alteration are recognized. VD seems to act

Genomic instability and genetic heterogeneity in aging: insights from clonal hematopoiesis (CHIP), monoclonal gammopathy (MGUS), and monoclonal B-cell lymphocytosis (MBL).

Aging is a multifaceted process characterized by a gradual decline in physiological function and increased susceptibility to a range of chronic diseases. Among the molecular and cellular mechanisms driving aging, genomic instability is a fundamental hallmark, contributing to increased mutation load and genetic heterogeneity within cellular populations. This review explores the role of genomic instability and genetic heterogeneity in aging in the hematopoietic system, with a particular focus on clonal hematopoiesis of indeterminate potential (CHIP), monoclonal gammopathy of undetermined signifi

Роль антиоксидантов в множестве миеломы: диагностика, прогнозирование и терапевтическое применение: обзор сюжета.

Множественная миэлома (ММ) — злокачественная клетка B-клеток с моноклональными плазменными клетками, производящими нефункциональные иммуноглобулины. Она по-прежнему неизлечима из-за de novo или приобретенного сопротивления злокачественных клеток стандартным химиотерапиям. Таким образом, понимание механизма терапевтического сопротивления имеет важнейшее значение для разработки более эффективных мер вмешательства и определения новых целей лечения. MM - это разнородная болезнь, характеризующаяся сложными генетическими изменениями, которые имеют решающее значение для прогнозирования стратификации.

A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease.

Alzheimer's disease (AD) is a heterogeneous neurodegenerative disease driven by pathological depositions of proteins that accumulate over decades. Compelling genetic and neurobiological evidence suggests that amyloid accumulation in the brain initiates and drives early-stage AD. Measurement of fibrillar amyloid has been pivotal to the development and approval of disease-slowing treatments. Various biomarkers of AD pathophysiology provide evidence of target engagement and downstream effects on disease progression, and their use as surrogate endpoints may help identify and expeditiously bring ne

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.

The prognosis of patients with metastatic breast cancer remains poor, and thus novel therapeutic approaches are needed. Capecitabine, which is commonly used for metastatic breast cancer in different settings, is an inactive prodrug that takes advantage of elevated levels of thymidine phosphorylase (TP), a key enzyme that is required for its conversion to 5-fluororacil, in tumors. We demonstrated that histone deacetylase inhibitors (HDACi), including low anticonvulsant dosage of VPA, induced the dose- and time-dependent up-regulation of TP transcript and protein expression in breast cancer cell

Anaplastic thyroid cancer cells reduce CD71 levels to increase iron overload tolerance.

BackgroundFollicular thyroid cancer (FTC) is a prevalent form of differentiated thyroid cancer, whereas anaplastic thyroid cancer (ATC) represents a rare, fast-growing, undifferentiated, and highly aggressive tumor, posing significant challenges for eradication. Ferroptosis, an iron-dependent cell death mechanism driven by the excessive production of reactive oxygen species and subsequent lipid peroxidation, emerges as a promising therapeutic strategy for cancer. It has been observed that many cancer cells exhibit sensitivity to ferroptosis, while some other histotypes appear to be resistant,

Роль TP53 и FGFR2 в ходе лечения эндометического рака

Заболеваемость и смертность, вызываемые раком эндомеза, по-прежнему растут во всем мире. В последние годы была предложена новая система стратификации опухолей, основанная на статусе мутации POLE, TP53 и стабильности микроспутников. Цель этого исследования заключалась в анализе обширной группы по генам, которые потенциально могут быть связаны с геномомом эндомеального рака у польского населения. One hundred и three В исследование были зачислены белые пациентки с подтвержденным эндомеозным раком. Мы провели последовательность с использованием панели Hot Spot Illumin и стабильности микроспутников